Skip to content

Opko Health OPK Other Commercial Liabilities

Other Commercial Liabilities at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
ALN
Alnylam PharmaceuticalsALNY
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Amgen logo
AmgenAMGN
GeneDx Holdings logo
GeneDx HoldingsWGS

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Gross profit$45.8M+7.4%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%
Free cash flow-$21.1M+44.0%

Valuation

See full
Market cap$1.13B-22.4%
P/S1.9×-0.2×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Return on equity-16.9%-21.7pp
Debt / equity0.0×
Current ratio3.6×+1.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's other commercial liabilities?
Opko Health (OPK) reported other commercial liabilities of $83.48M in Q1 2026.
How has Opko Health's other commercial liabilities changed year-over-year?
Opko Health's other commercial liabilities decreased by 26.3% year-over-year, from $113.21M to $83.48M.
What is the long-term trend for Opko Health's other commercial liabilities?
Over 5 years (2020 to 2025), Opko Health's other commercial liabilities has grown at a -18.9% compound annual growth rate (CAGR), from $240.87M to $84.41M.